Literature DB >> 715770

Interference with fluorimetric assay of catecholamine by labetalol.

K Kobayashi, Y Miura, H Tomioka, H Sakuma, M Adachi, K Abe, K Yoshinaga.   

Abstract

Influence of labetalol and 5-(1-hydroxy-2-aminoethyl)salicylamide (SA), a part of the chemical structure of labetalol, on the fluorimetric assay of catecholamine (CA) was studied. Both labetalol and SA have a weak but significant fluorescence which is indistinguishable from that of CA with peaks of excitation/emission wavelengths at 410/490. It is thus concluded that an apparent increase in urinary CA observed in patients receiving labetalol is caused by the contamination of labetalol and/or its metabolite, and that the evaluation of urinary CA in hypertensive patients must be done prior to the use of labetalol to avoid any confusion in diagnosis of pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 715770     DOI: 10.1620/tjem.126.201

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  3 in total

1.  Relationship of plasma catecholamines to blood pressure in hypertensive patients during beta-adrenoceptor blockade with and without intrinsic sympathomimetic activity.

Authors:  R Kirsten; B Heintz; D Böhmer; K Nelson; S Roth; D Welzel
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

2.  Erroneous diagnosis of phaeochromocytoma in hypertensive patient on labetalol.

Authors:  P M Bouloux; R M Featherstone; V Clement-Jones; L H Rees; J E Goligher
Journal:  J R Soc Med       Date:  1985-07       Impact factor: 5.344

3.  Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension.

Authors:  G Keusch; P Weidmann; W H Ziegler; R de Châtel; F C Reubi
Journal:  Klin Wochenschr       Date:  1980-01-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.